Archamps, June 29th, 2022 – Cathay Capital announces its investment in TransCure bioServices, alongside the management team and Financière Arbevel. With this transaction, TransCure bioServices will benefit from Cathay Capital’s healthcare expertise as well as its strategic and financial support to accelerate growth and global expansion.
Patrick Nef, PhD, co-founder and CEO of TransCure bioServices, said: “We have experienced a very high growth rate over the past 5-years, becoming a truly global leading and highly specialized CRO in predictive in vivo pharmacology with humanized mouse models. Today, we welcome Cathay Capital as a timely and natural partner for us as we start the next phase of our next journey, benefitting from their experience in healthcare and know-how in accompanying fast-growing companies internationally.”
Fabien Wesse, Managing Partner at Cathay Capital, added: “We are very happy to work with Patrick Nef, Sébastien Tabruyn and the management team to support them in the company’s ambitious project. TransCure bioServices benefits from unique scientific expertise on humanized mouse models across a variety of therapeutic areas, in a highly specialized rapidly growing preclinical market. We are delighted that they have chosen Cathay as partners and look forward to accompanying their growth by leveraging our global platform, ecosystem, and long-standing commitment to the healthcare industry.”
About TransCure bioServices SAS
TransCure bioServices SAS is a European CRO based in France offering preclinical predictive in vivo pharmacology testing services to international large pharmaceutical, biotech and academic customers. Uniquely designed preclinical models with functional human immune system and human hepatocytes/liver provide predictive power for drug profiling and smarter drug candidate selection for immuno-oncology, inflammation (IBD, SLE, MS, RA), auto-immune, infectious (HIV, Dengue), liver diseases, vaccines, and immuno-hepato toxicity (DMPK, ADME). If you are looking for check point inhibition, CART-cell designs, 100% IgG mAb, any drug profiling involving the human immune system or hu-liver, contact us at www.tcbioservices.com
About Cathay Capital
Cathay Capital Group is a global investment firm supporting companies at all stages throughout North America, Asia, Europe and Africa. By helping navigate the opportunities of globalization and sustainable transformation, Cathay is the partner of choice for companies aspiring to lead markets and make a positive impact. Its global platform connects people – from investors and entrepreneurs to management teams and leading corporations – across continents to share knowledge, the tools to scale, and achieve the extraordinary. Founded in 2007 with a strong entrepreneurial heritage, Cathay Capital now manages more than $4.5 billion in assets, has completed over 220 buyouts, growth and venture capital investments with the global reach and local expertise from offices in Paris, New York, Shanghai, Munich, San Francisco, Beijing, Singapore, Shenzhen and Tel Aviv. www.cathaycapital.com